The Generation and Preclinical Evaluation of Homodimeric Anti-Her-2 Antibodies

Abstract

Her-2/neu has been selected as a target for immunotherapy based on its prevalence on a variety of tumor cells and the poor prognosis associated with its overexpression. From a panel of a hundred alpha-Her-2 MAbs we have characterized eleven with the highest affinity for Her-2 for further study in the treatment of prostate cancer. Three were eventually chosen for testing as homodimers and all induced substantially more growth arrest and death in vitro than their corresponding monomers. Work has also begun converting a number of these MAbs into mouse/human chimeric IgG1/kappa into which we have incorporated cysteine residues for homodimer formation. These genetic dimers will be evaluated for efficacy in our in vitro models.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2001
Accession Number
ADA394258

Entities

People

  • Ellen S. Vitetta

Organizations

  • University of Texas at Dallas

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemical Compounds
  • Cysteine
  • Demographic Cohorts
  • Materials
  • Molecules
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Test And Evaluation

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Immunology
  • Polymer Science and Technology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech